2024-510893-25-00招募中3 期
Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled double-blind phase III study, comparing bevacizumab versus placebo (BRADI)
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 84
- 试验地点
- 18
- 主要终点
- - Corticosteroids dose at Cycle 1 Day 1 (C1D1) and at 3 months (90 days, End of treatment (EOT) visit) - NANO (Neurological Assessment in Neuro-Oncology) score (60) at C1D1 and at 3 months (90 days -EOT visit) The NANO scale evaluates 8 major domains of neurologic function that are most relevant to patients with supratentorial, infratentorial, and brainstem tumors
研究概览
简要总结
To investigate whether the addition of bevacizumab to standard corticosteroid therapy, compared to corticosteroid therapy plus placebo, results in greater efficacy at 3 months (90 days) on decrease in corticosteroids and in neurological symptoms associated with radionecrosis (RN) after radiotherapy for brain metastases
研究设计
- 分配方式
- Randomized
- 主要目的
- Randomisation And Treatment
- 盲法
- Double (Subject, Investigator)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Patient with a diagnosis of radionecrosis based on a clinical onset of symptoms and radiological findings of RN following radiotherapy, with or without pathological confirmation: o MRI evidence to support the diagnosis of RN (transient increase in irradiated lesion volume -FLAIR hypersignal and/or enhanced portion- without rCBV increase) o COMBINED with nuclear medicine imaging: biphasic 18FDG-PET-TDM/MRI according to Horky or 18F-FDOPA PET TDM/MRI with stage 0-1 according to Lizarraga
- •Signed informed consent;
- •Patient affiliated to a social security scheme.
- •Symptoms are persistent or worsening despite administration of corticosteroids: at least 1 mg/kg/d of prednisolone or equivalent: - Corticoresistant: neurological symptoms despite administration of at least 2 weeks of 1 mg/kg/d prednisolone or equivalent; - Corticodependant: worsening of neurological signs or symptoms after an initial improvement when weaning off steroids at a dose < 0.5 mg/kg/d prednisolone or equivalent;
- •Patients must have received the last cranial irradiation with photons or proton therapy for brain metastases ≥ 3 months with one or more sequences;
- •Age ≥ 18-year-old;
- •ECOG performance status score ≤ 2 or Karnofsky Performance Score (KPS) ≥ 50
- •Life expectancy of at least 3 months assessed by graded prognostic score (DS-GPA) score 0.5 or greater;
- •Patient who has never received Bevacizumab for the indication of radionecrosis.
- •Adequate organ function: Bone marrow function • Absolute Neutrophil Count (ANC) ≥ 1,500/mm3 Platelet Count ≥ 100,000/mm3, Haemoglobin ≥ 10 g/dL (allowing transfusion or other intervention to achieve this minimum haemoglobin) Coagulation • International normalized ratio (INR) or prothrombin time < 1.5 × ULN Renal function • No proteinuria with urine dipstick for proteinuria > 2+ • Serum creatinine ≤1.5 x ULN or creatinine clearance ≥50 mL/min (measured or calculated using the CDK-EPI formula) Hepatic Function • Total bilirubin ≤1.5 x the upper limit of normal (ULN) • Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤3 x ULN
- •Women of childbearing potential must use effective contraceptive measures during the treatment and for 6 months following its cessation
排除标准
- •Evidence of active bleeding or a pathological condition at high risk of bleeding: CNS hemorrhage, bleeding diathesis or coagulopathy, hemoptysis (>2.5ml of bright red blood per episode), evidence of history of bowel obstruction, abdominal fistula, or gastrointestinal tract perforation or gastro intestinal abscess occurring less than 28 days prior study entry
- •Major surgical procedure or significant traumatic injury less than 28 days prior study entry; minor surgery within 3 days prior to initiation of study treatment;
- •Clinically significant cardiovascular disease such as uncontrolled arterial hypertension (BP ≥160 mm Hg or diastolic BP ≥100 mm Hg despite maximal medical therapy), cerebrovascular event, myocardial infarction, cardiac arrhythmias, unstable angina, or congestive heart failure within the last 6 months;
- •History of hypertensive crisis or hypertensive encephalopathy
- •Patients scheduled to undergo head and neck, thoracic, or abdominal radiotherapy during the study treatment
- •Prior bevacizumab ≤ 3 months before randomization;
- •Progressive brain metastases;
- •New cerebral metastasis detected during the inclusion imaging evaluation;
- •Prior diagnosis of Posterior Reversible Encephalopathy Syndrome (PRES) with bevacizumab;
- •Hypersensitivity known to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies.
- •History of severe allergic anaphylactic reactions to bevacizumab
- •Patients with a known hypersensitivity to athe active substance or to any of the excipients of bevacizumab are not eligible for participation;
- •Patients with a contraindication to the treatment with bevacizumab according to the European SmPC
- •Patient pregnant and/or nursing;
- •Mental impairment (psychiatric illness/social situations) that may compromise the ability of the patient to give informed consent and comply with the requirements of the study;
- •Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.
- •Grade 4 venous thromboelism and peripheral arterial thrombus;
- •Evidence of very high intracranial pressure that suggests brain hernia and needs emergency surgery;
结局指标
主要结局
- Corticosteroids dose at Cycle 1 Day 1 (C1D1) and at 3 months (90 days, End of treatment (EOT) visit) - NANO (Neurological Assessment in Neuro-Oncology) score (60) at C1D1 and at 3 months (90 days -EOT visit) The NANO scale evaluates 8 major domains of neurologic function that are most relevant to patients with supratentorial, infratentorial, and brainstem tumors
- Corticosteroids dose at Cycle 1 Day 1 (C1D1) and at 3 months (90 days, End of treatment (EOT) visit) - NANO (Neurological Assessment in Neuro-Oncology) score (60) at C1D1 and at 3 months (90 days -EOT visit) The NANO scale evaluates 8 major domains of neurologic function that are most relevant to patients with supratentorial, infratentorial, and brainstem tumors
次要结局
- a) Safety assessed using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0 for up to 90 days following C1D1
- b) Quality of life is measured with EORTC QLQ-C30 and BN20 (59) ; assessed at C1D1, C2D1, C3D1, C4D1 and EOT visit
- c) Success assessed using: - Corticosteroid’s dose: at C1D1 and at 3 months (90 days) - NANO score: at C1D1, C2D1, C3D1, C4D1 and EOT visit - EORTC QLQC-30 and BN20 scores: at C1D1, C2D1, C3D1, C4D1 and EOT visit
- d) Clinical changes assessed using: - Patient Global Impression of Change (PGIC) questionnaire (from 1 to 7) and Scale (from 0 to 10): at C4D1 and EOT visit - NANO score: at C1D1, C2D1, C3D1, C4D1 and EOT visit
- e) volume on brain MRI T1 post-gadolinium and T2-weighted FLAIR: at EOT visit
- f) Duration of response assessed using: - NANO scale: every 3 months until 2 years - dose of corticosteroids: every 3 months until 2 years
- g) Corticosteroids dose at 3 months and vital status up to 3 months
- h) Correlative biomarkers (ceramide, VEGF, angiopoietin, TGF-alpha) and nuclear medicine images
研究者
Luc OLLIVIER
Scientific
Institut De Cancerologie De L Ouest
研究点 (18)
Loading locations...
相似试验
终止
2 期
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain MetastasesRadionecrosisBrain MetastasesNCT02490878Alliance for Clinical Trials in Oncology19
Unknown
2 期
Treatment of Bevacizumab Followed by Steroid in RNAdverse Effect of Radiation TherapyBrain InjuriesNasopharyngeal CarcinomaNCT04553510Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University86
招募中
3 期
Bevacizumab for the treatment of cerebral RAdiation Induced NecrosiS (BRAINS) study: A multicenter, open-label, randomized clinical trial to assess the clinical efficacy and cost-effectiveness of bevacizumab versus corticosteroids as first-line treatment in patients with symptomatic cerebral radiation necrosis after radiation for high grade glioma or brain metastases2024-512466-34-00Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting408
已完成
3 期
As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent AsthmaAsthmaNCT00382889Chiesi Farmaceutici S.p.A.480
已完成
3 期
KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAPCommunity-acquired PneumoniaNCT03474991Julia Bielicki510